Opioid-treatment maker again accused of anti-competitive practices

After being sued by Ohio and other states, the maker of important opioid-addiction treatment medications again has been accused of anti-competitive practices.

An article published Thursday in the New England Journal of Medicine said Suboxone maker Indivior and its former parent company, Reckitt Benckister, used four improper schemes to avoid competition and inflate the price of drugs by hundreds of millions of dollars per year.